The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AEGLEA BIOTHERAPEUTICS INC | COM | 00773J103 | 258 | 112,044 | SH | SOLE | 112,044 | 0 | 0 | ||
DIFFUSION PHARMACEUTICALS IN | COM PAR | 253748305 | 22 | 89,848 | SH | SOLE | 89,848 | 0 | 0 | ||
ABG ACQUISITION CORP I | CL A SHS | G00496102 | 4,918 | 501,300 | SH | SOLE | 501,300 | 0 | 0 | ||
SONENDO INC | COM | 835431107 | 2,197 | 547,945 | SH | SOLE | 547,945 | 0 | 0 |